OncoMatch/Leukemia — Acute Myeloid (AML)/RUNX1
Leukemia — Acute Myeloid (AML)RUNX1 Clinical Trials
RUNX1 mutations occur in 10–15% of AML, classified as adverse-risk by ELN 2022 guidelines, and are often associated with antecedent MDS or myelodysplastic features. RUNX1-mutant AML is a component of familial platelet disorder with predisposition to AML (FPD-AML) and has a distinct transcriptional profile. Trials explore menin inhibitors, venetoclax-based regimens, and novel agents targeting co-occurring mutations in this subgroup.
Top recruiting RUNX1 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
M.D. Anderson Cancer Center
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
University of Alabama at Birmingham
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Washington University School of Medicine
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
St. Petersburg State Pavlov Medical University